期刊文献+

羧酸酯酶在抗肿瘤药物研究中的作用

The Role of Carboxylesterase in Anti- tumor Drug Research
下载PDF
导出
摘要 哺乳动物羧酸酯酶(carboxylesterase,CESs)是一个多基因家族,其基因产物定位于多种组织的内质网中.羧酸酯酶能有效催化酯类和酰胺类化合物水解,承担多种前体药物的生物转换功能药物.综述羧酸酯酶的结构、分类、生化性质、作用机制及其在抗肿瘤药物研究中的最新进展. Mammalian carboxylesterases CESs represent a muhigene family, the products of which are localized in the endoplasmic reticulum of many tissues. CESs play an important role in the hydrolytic biotransformation of ester and amide-containing chemicals. A significant number of prodrugs are metabolized by carboxylesterase. This review covers current developments in the structure, function, biochemical characteristics, mechanisms and progress in the anti-tumor drug-researches of carboxylesterases.
作者 田园 卿晨
出处 《昆明医科大学学报》 CAS 2015年第1期157-161,共5页 Journal of Kunming Medical University
基金 国家科技部重大新药创制专项基金资助项目(2011ZX09401-026)
关键词 羧酸酯酶 药物代谢 抗肿瘤药物 Carboxylesterases Drug metabolism Anti-tumor drug
  • 相关文献

参考文献2

二级参考文献10

  • 1刘彤华.表皮生长因子受体家族与靶向性抗癌治疗[J].中华病理学杂志,2006,35(10):577-579. 被引量:21
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 4Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma pmtuberans and giant-cell fibmblastoma. Nat Genet, 1997,15( 1 ) :95-98.
  • 5West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Nail Aead Sei U S A,2006,103(3) : 690-695.
  • 6Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer, 2006,42 ( 8 ) : 1093-1103.
  • 7Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol, 2006,24(29) :4764-4774.
  • 8Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell, 2002,2 : ( 2 ) 117-125.
  • 9Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med,2005,353( 19): 2012-2024.
  • 10周成英.羟基喜树碱双途径联合化疗治疗中晚期胃肠癌[J].中国肿瘤临床与康复,1999,6(4):91-92. 被引量:3

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部